Combination Therapy of Anthracyclines for Children With Nephroblastoma

Launched by SHENGJING HOSPITAL · Mar 25, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a combination therapy using certain chemotherapy drugs called anthracyclines to treat children with nephroblastoma, which is a type of kidney cancer. The goal is to find out how effective this treatment is and what side effects it may cause in children aged 6 months to 14 years who have been diagnosed with this condition.

To participate in the trial, children must be in the specified age range, have a confirmed diagnosis of nephroblastoma, and meet certain health criteria. For example, they should not have any serious heart issues or other major health problems that could complicate treatment. Before joining, families will need to give their informed consent, meaning they understand the study and agree to participate. While the trial is not yet recruiting participants, it aims to provide valuable information about how this treatment can help young patients with nephroblastoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 6 months old to 14 years old.
• • 2. No smoking history.
• • 3. Pathologically confirmed nephroblastoma.
• • 4. Informed consent and assent has been obtained before any study assessment is performed.
• • 5. Good compliance.
• • 6. Need to be applied to anthracycline chemotherapy according to the diagnosis and treatment recommendations for Chinese children with nephroblastoma (current version CCCG-WT-2016).
• • 7. Need to be applied to doxorubicin according to the diagnosis and treatment recommendations for children with nephroblastoma (CCCG-WT-2016).
• Exclusion Criteria:
• • 1. Patients with cardiovascular disease in addition to nephroblastoma.
• • 2. Patients with digestive, neurological, circulatory, renal or liver disease, blood disorders or growth abnormalities unrelated to the tumor.
• • 3. Patients have been treated with chemotherapy or cardiotoxic nephrotoxic drugs in the past 4 weeks.
• • 4. Patients have participated in other clinical trials in the past 4 weeks.
• • 5. Patients with mediastinal disease.
• • 6. Patients who have undergone mediastinal radiotherapy due to other tumors or received other treatments that may cause heart damage.